On March 4, 2025, KeYe Life launched the Phase I clinical trial for its KY1 product (KY386 Injection) at Ruijin Hospital in Shanghai. This trial marks a significant step for the first small molecule inhibitor targeting a RNA helicase DHX33, advancing its clinical research at another major medical center.

KY1, an innovative drug developed by KeYe Life, targets the DHX33 protein, which is over-expressed in various cancers and promotes cancer cell proliferation. By inhibiting DHX33, KY1 induces cell death in cancer cells but sparing normal cells, offering a novel mechanism for cancer treatment. The open-label, dose-escalation trial will evaluate the  safety, tolerability, and pharmacokinetics for KY1 in humans.

Experts from Ruijin Hospital, KeYe Life, and the CRO team attended the launch meeting, discussing the trial's protocol, enrollment and exclusion criteria, as well as operational details. Comprehensive training was provided to ensure smooth trial execution and data accuracy.

Following its launch at Shandong Cancer Hospital, this trial at Ruijin Hospital represents another milestone in KY1's clinical development, bringing hope to cancer patients. KeYe Life remains committed to scientific innovation and collaboration with research centers to advance KY1's progress, aiming to deliver a safe and effective treatment solution for cancer patients.